The document contains confidential information about patient flows for colorectal cancer (CRC), lung cancer (LCA), and other cancers (OCA). It provides data on the total number of patients for each cancer type, percentages that receive different treatments like surgery, chemotherapy, or no treatment, and the numbers of patients projected to be able to afford advanced treatments.

1. Confidential – for internal use only
1
PatientFlowCRC
TotalCRCPatients
5,180
Operable (70%)
3,626
Inoperable(30%)
1,554
Go for Surgery (85%)
3,082
Go for FurtherTreatment
2,773
Systemic Chemotherapy(CT)
(70%)
1,941
90%
Oral CT(5%)
138
Radiotherapy (40%)
1,109
Affordable for
advanced treatment
150
Ref.:Patientsno.Globocan2018, MarketResearch2015

2. Confidential – for internal use only
Patient flow - LCA
Total LCA Patients
12,374
SCLC (20%)
2,473
NSCLC (80%)
9,900
Adenocarcinom
(40%)
3,960
Large cell
(30%)
2,970
Squamous cell
(30%)
2,970
Surgery (15%)
594
Other treatment (55%)
2,178
Radiotherapy
871
Chemotherapy
1,306
Affordable for
advanced
30
Ref.: Patient no. Globocan 2018, Market research 2015
No treatment (30%)
1,980

3. Confidential – for internal use only
Patient flow - OCA
3
OCA New Patinets
3,063
Operable (85%)
2,603
In-operable (15%)
459
Surgery (90%)
2,342
Continue treatment after
1,170
Further Treatment
1,630
Chemotherapy
965
Best supportive care
335
Affordable
treatment
50
Ref.: Patients no. Globocan 2018, Market Research 2015
No treatment (20%)
330